Aktis Oncology (NASDAQ:AKTS – Get Free Report) and Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations and risk.
Analyst Recommendations
This is a summary of recent ratings and recommmendations for Aktis Oncology and Zealand Pharma A/S, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aktis Oncology | 1 | 0 | 9 | 1 | 2.91 |
| Zealand Pharma A/S | 0 | 9 | 1 | 1 | 2.27 |
Aktis Oncology currently has a consensus price target of $35.62, suggesting a potential upside of 114.35%. Given Aktis Oncology’s stronger consensus rating and higher possible upside, research analysts plainly believe Aktis Oncology is more favorable than Zealand Pharma A/S.
Profitability
This table compares Aktis Oncology and Zealand Pharma A/S’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aktis Oncology | -727.04% | -26.86% | -18.13% |
| Zealand Pharma A/S | 67.13% | 19.70% | 18.27% |
Institutional and Insider Ownership
28.8% of Aktis Oncology shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Earnings and Valuation
This table compares Aktis Oncology and Zealand Pharma A/S”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aktis Oncology | $6.50 million | 137.87 | -$63.73 million | ($0.82) | -20.27 |
| Zealand Pharma A/S | $1.40 billion | 1.82 | $977.29 million | $6.03 | 5.89 |
Zealand Pharma A/S has higher revenue and earnings than Aktis Oncology. Aktis Oncology is trading at a lower price-to-earnings ratio than Zealand Pharma A/S, indicating that it is currently the more affordable of the two stocks.
Summary
Zealand Pharma A/S beats Aktis Oncology on 6 of the 11 factors compared between the two stocks.
About Aktis Oncology
Aktis Oncology, Inc. is a clinical-stage biotechnology company developing targeted radiopharmaceuticals for solid tumors. Its approach uses small protein-based molecules designed to bind cancer-associated targets and deliver radioactive payloads to tumor cells. The company’s pipeline includes investigational programs directed at targets found on solid tumors, including Nectin-4. These candidates are being developed for potential use in patients with advanced cancers; they are not approved for commercial use.
About Zealand Pharma A/S
Zealand Pharma A/S is a biotechnology company headquartered in Copenhagen, Denmark. Founded in 1998, it discovers and develops peptide-based medicines, with a focus on metabolic diseases and rare conditions. The company’s portfolio has included Zegalogue (dasiglucagon), an injectable treatment approved in the United States for severe hypoglycemia in people with diabetes. Zealand also develops investigational medicines for areas such as obesity, liver disease and rare gastrointestinal disorders, and works with pharmaceutical partners to advance and commercialize selected programs.
Receive News & Ratings for Aktis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aktis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
